Journal
JOURNAL OF CANCER
Volume 3, Issue -, Pages 158-165Publisher
IVYSPRING INT PUBL
DOI: 10.7150/jca.4211
Keywords
hepatocellular carcinoma; sorafenib; panobinostat; deacetylase inhibitor
Categories
Funding
- Novartis Pharma GmbH, Nuremberg, Germany
Ask authors/readers for more resources
Advanced hepatocellular carcinoma still represents an unmet medical need that has only a limited overall survival despite the introduction of the multi-kinase inhibitor sorafenib. Recently, inhibitors of histone and other protein deacetylases have been established as novel therapeutic approaches to cancer diseases. We here review the molecular rationale for combining these two novel targeted therapies and report a patient with metastasized hepatocellular carcinoma who showed a partial remission of primary and metastatic lesions for five months after a combination therapy with sorafenib and the orally available pan-deacetylase inhibitor panobinostat.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available